Phreesia, Inc. $PHR Shares Bought by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its stake in Phreesia, Inc. by 385.1% during the first quarter, acquiring an additional 137,904 shares and owning 0.30% of the company worth $4.44 million.
• Insider activity includes the sale of 17,445 shares by David Linetsky, representing a 9.11% decrease in ownership, while a total of 119,874 shares were sold by insiders over the past ninety days.
• Analysts have issued favorable ratings, with KeyCorp raising its price target for Phreesia from $28.00 to $35.00, and a consensus of eleven analysts rating the company as a "Buy."

Trexquant Investment LP boosted its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 385.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 173,717 shares of the company's stock after acquiring an additional 137,904 shares during the quarter. Trexquant Investment LP owned 0.30% of Phreesia worth $4,440,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PHR. KBC Group NV acquired a new position in Phreesia in the first quarter valued at $74,000. CWM LLC lifted its stake in shares of Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after purchasing an additional 3,671 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after purchasing an additional 1,825 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Phreesia by 1,023.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock worth $142,000 after purchasing an additional 5,156 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after purchasing an additional 5,621 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Stock Up 2.8%

Shares of NYSE PHR traded up $0.87 during midday trading on Thursday, reaching $31.31. 1,472,338 shares of the company's stock were exchanged, compared to its average volume of 549,541. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $32.76. The stock has a market capitalization of $1.86 billion, a PE ratio of -42.30 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. The business's fifty day moving average price is $28.28 and its two-hundred day moving average price is $26.55.

Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.During the same quarter last year, the business earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. Analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.

Insider Transactions at Phreesia

In related news, insider David Linetsky sold 17,445 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $29.73, for a total value of $518,639.85. Following the completion of the sale, the insider directly owned 174,002 shares of the company's stock, valued at $5,173,079.46. The trade was a 9.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of the business's stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the sale, the director directly owned 22,037 shares of the company's stock, valued at approximately $609,763.79. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,874 shares of company stock valued at $3,587,618 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Mizuho assumed coverage on Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price objective on the stock. Truist Financial boosted their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. KeyCorp boosted their price objective on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Finally, Stephens restated an "overweight" rating and set a $32.00 price objective on shares of Phreesia in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. According to MarketBeat.com, Phreesia has an average rating of "Buy" and a consensus target price of $32.54.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.